On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia
, A., Clinical and Experimental Medicine, doi:10.1007/s10238-023-01010-7, Feb 2023
Letter to the editor discussing the choice of molnupiravir and paxlovid as the only approved COVID-19 antiviral therapies in Australia in 2022, despite other therapies showing higher efficacy and lower cost in clinical trials. The author questions why better performing therapies were prevented and notes that the government should follow the science in selecting therapies. The author also compares COVID-19 fatalities in the US, UAE, and worldwide average, suggesting the UAE had lower fatalities due to permitting antiviral therapies that were obstructed in the US and Australia.
Potential risks of molnupiravir include the creation of dangerous variants, and mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity1-15. Multiple analyses have identified variants potentially created by molnupiravir16-20.
Study covers paxlovid and molnupiravir.
1.
Swanstrom et al., Lethal mutagenesis as an antiviral strategy, Science, doi:10.1126/science.abn0048.
2.
Hadj Hassine et al., Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity, Viruses, doi:10.3390/v14040841.
3.
Shum, C., An investigational study into the drug-associated mutational signature in SARS-CoV-2 viruses, The University of Hong Kong, PhD Thesis, hub.hku.hk/handle/10722/344396.
4.
Waters et al., Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir, Environmental and Molecular Mutagenesis, doi:10.1002/em.22471.
5.
Huntsman, M., An assessment of the reproductive toxicity of the anti-COVID-19 drug molnupiravir using stem cell-based embryo models, Master's Thesis, scholarspace.manoa.hawaii.edu/items/cd11342c-b4dc-44c0-8b44-ce6e3369c40b.
6.
Huntsman (B) et al., Detection of developmental toxicity of the anti-COVID-19 drug molnupiravir using gastruloid-based in vitro assays, Toxicological Sciences, doi:10.1093/toxsci/kfaf093.
7.
Zibat et al., N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody, iScience, doi:10.1016/j.isci.2023.107786.
8.
Shiraki et al., Convenient screening of the reproductive toxicity of favipiravir and antiviral drugs in Caenorhabditis elegans, Heliyon, doi:10.1016/j.heliyon.2024.e35331.
9.
Gruber et al., Molnupiravir increases SARS‐CoV‐2 genome diversity and complexity: A case‐control cohort study, Journal of Medical Virology, doi:10.1002/jmv.29642.
10.
Marikawa et al., An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations, Reproductive Toxicology, doi:10.1016/j.reprotox.2023.108475.
11.
Rahman, M., Elucidation of the DNA repair mechanisms involved in the repair of DNA damage caused by the Arabinosides and Anti-COVID-19 drugs, tokyo-metro-u.repo.nii.ac.jp/records/2000972.
12.
Zhou et al., β-D-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, doi:10.1093/infdis/jiab247.
13.
Chamod et al., Molnupiravir Metabolite--N4-hydroxycytidine Causes Cytotoxicity and DNA Damage in Mammalian Cells in vitro: N4-hydroxycytidine Induced Cytotoxicity DNA Damage, Asian Medical Journal and Alternative Medicine, 23:3, asianmedjam.com/index.php/amjam/article/view/1448.
14.
Standing et al., Randomized controlled trial of molnupiravir SARS-CoV-2 viral and antibody response in at-risk adult outpatients, Nature Communications, doi:10.1038/s41467-024-45641-0.
15.
Mori et al., Reactive oxygen species-mediated cytotoxic and DNA-damaging mechanism of N4-hydroxycytidine, a metabolite of the COVID-19 therapeutic drug molnupiravir, Free Radical Research, doi:10.1080/10715762.2025.2469738.
16.
Focosi et al., The fitness of molnupiravir-signed SARS-CoV-2 variants: imputation analysis based on prescription counts and GISAID analyses by country, Intervirology, doi:10.1159/000540282.
17.
Sanderson et al., A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, Nature, doi:10.1038/s41586-023-06649-6.
18.
Fountain-Jones et al., Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study, The Lancet Microbe, doi:10.1016/S2666-5247(23)00393-2.
19.
Kosakovsky Pond et al., Anti-COVID drug accelerates viral evolution, Nature, doi:10.1038/d41586-023-03248-3.
21.
Shen et al., Carboxylesterase Factors Influencing the Therapeutic Activity of Common Antiviral Medications Used for SARS-CoV-2 Infection, Pharmaceutics, doi:10.3390/pharmaceutics17070832.
22.
Bacigalupo et al., Unveiling patenting strategies of therapeutics and vaccines: evergreening in the context of COVID-19 pandemic, Frontiers in Medicine, doi:10.3389/fmed.2023.1287542.
23.
Boretti, A., On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia, Clinical and Experimental Medicine, doi:10.1007/s10238-023-01010-7.
24.
Anonymous, Treating a Pandemic Respiratory Disease with a Mutagen is a Doomsday Scenario, Authorea, doi:10.22541/au.163854323.34557301/v1.
Boretti et al., 8 Feb 2023, preprint, 1 author.
Contact: a.a.boretti@gmail.com.
Abstract: Clinical and Experimental Medicine (2023) 23:4033–4034
https://doi.org/10.1007/s10238-023-01010-7
CORRESPONDENCE
On the choice of Molnupiravir and Paxlovid as the only antivirals
permitted for COVID‑19 infection in Australia
Alberto Boretti1
Received: 14 January 2023 / Accepted: 23 January 2023 / Published online: 8 February 2023
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023
To the Editor,
Australia has prohibited to use the of COVID-19 antiviral therapies which were prohibited in Europe and North
America, despite countries permitting these therapies to
achieve much lower fatalities due to COVID-19 infection.
Then, in 2022, with COVID-19 starting to be downgraded
in many jurisdictions to the normal flu, with about the same
of flu fatalities, irrespective of vaccination status, Australia
finally permitted two antiviral drugs, which are not the more
effective, nor the cheaper in between those with trial information in the scientific literature, and only for selected categories (Fig. 1). The permitted oral treatment is Lagevrio
(Molnupiravir) and Paxlovid (nirmatrelvir and ritonavir).
According to the database of c19early.org [1], collecting all
the published data of all the trials about COVID-19 therapies, currently (January 2023) 36 of 48 treatments analyzed show statistically significant efficacy or harm, defined
as ≥ 10% decreased risk or > 0% increased risk from ≥ 3
studies. Paxlovid, listed since the second half of 2022, has
delivered so far an improvement of 40% based on 20 studies
including 26,783 patients. One treatment costs US$ 529. It
is ranked no. 20 for efficacy in All studies (pooled effects, all
stages). Molnupiravir, listed since the second half of 2021,
has delivered so far an improvement of 20% based on 25
studies including 69,837 patients. One treatment costs US$
707. It is ranked no. 41 for efficacy in All studies. Technically, at the time of approval in Australia [2], there was not
Fig. 1 Timeline of introduction
of COVID-19 therapies according to www.c19early.org [1].
Credit www.c19early.org
* Alberto Boretti
a.a.boretti@gmail.com
1
Johnsonville Road, Johnsonville, 6037 Wellington ,
New Zealand
13
Vol.:(0123456789)
4034
Clinical and Experimental Medicine (2023) 23:4033–4034
Fig. 2 Daily new COVID19 deaths per million people
according to www.ourworldin
data.org [3]. Credit www.ourwo
rldindata.org
enough data to support the use of Paxlovid. The Australian
government signed a contract with Merck Sharp & Dohme’s
(MSD) for the supply of Lagevrio, and with Pfizer for Paxlovid. The rank of c19study suffers from the time of the
introduction of one therapy, as the initial COVID-19 virus
was much less infectious but much more lethal than the latest
variants, of much-reduced lethality but increased infectivity,
as it was with the Spanish Flu, Fig. 2 [3]. The graph compares the fatalities in the United States and the United Arab
Emirates with the world average. The United Arab Emirates permitted since the beginning of the pandemic the use
of antiviral therapies which were otherwise obstructed in
the United States and Australia, also in the early stages of
infection [4, 5]. Therapies more recently introduced, such
as Molnupiravir and especially Paxlovid, are advantaged vs.
those introduced earlier. Why better performing therapies
were and are prevented, and why this selection, is a scientific
mystery. Should not the government follow science in the
selection of..
DOI record:
{
"DOI": "10.1007/s10238-023-01010-7",
"ISSN": [
"1591-9528"
],
"URL": "http://dx.doi.org/10.1007/s10238-023-01010-7",
"alternative-id": [
"1010"
],
"assertion": [
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Received",
"name": "received",
"order": 1,
"value": "14 January 2023"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "Accepted",
"name": "accepted",
"order": 2,
"value": "23 January 2023"
},
{
"group": {
"label": "Article History",
"name": "ArticleHistory"
},
"label": "First Online",
"name": "first_online",
"order": 3,
"value": "8 February 2023"
},
{
"group": {
"label": "Declarations",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 1
},
{
"group": {
"label": "Conflict of interest",
"name": "EthicsHeading"
},
"name": "Ethics",
"order": 2,
"value": "The authors declare no competing interests."
},
{
"label": "Free to read",
"name": "free",
"value": "This content has been made available to all."
}
],
"author": [
{
"affiliation": [],
"family": "Boretti",
"given": "Alberto",
"sequence": "first"
}
],
"container-title": "Clinical and Experimental Medicine",
"container-title-short": "Clin Exp Med",
"content-domain": {
"crossmark-restriction": false,
"domain": [
"link.springer.com"
]
},
"created": {
"date-parts": [
[
2023,
2,
8
]
],
"date-time": "2023-02-08T18:25:07Z",
"timestamp": 1675880707000
},
"deposited": {
"date-parts": [
[
2023,
10,
31
]
],
"date-time": "2023-10-31T20:07:01Z",
"timestamp": 1698782821000
},
"indexed": {
"date-parts": [
[
2023,
11,
1
]
],
"date-time": "2023-11-01T06:30:17Z",
"timestamp": 1698820217290
},
"is-referenced-by-count": 0,
"issue": "7",
"issued": {
"date-parts": [
[
2023,
2,
8
]
]
},
"journal-issue": {
"issue": "7",
"published-online": {
"date-parts": [
[
2023,
11
]
]
}
},
"language": "en",
"license": [
{
"URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
2,
8
]
],
"date-time": "2023-02-08T00:00:00Z",
"timestamp": 1675814400000
}
},
{
"URL": "https://www.springernature.com/gp/researchers/text-and-data-mining",
"content-version": "vor",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2023,
2,
8
]
],
"date-time": "2023-02-08T00:00:00Z",
"timestamp": 1675814400000
}
}
],
"link": [
{
"URL": "https://link.springer.com/content/pdf/10.1007/s10238-023-01010-7.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://link.springer.com/article/10.1007/s10238-023-01010-7/fulltext.html",
"content-type": "text/html",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://link.springer.com/content/pdf/10.1007/s10238-023-01010-7.pdf",
"content-type": "application/pdf",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "297",
"original-title": [],
"page": "4033-4034",
"prefix": "10.1007",
"published": {
"date-parts": [
[
2023,
2,
8
]
]
},
"published-online": {
"date-parts": [
[
2023,
2,
8
]
]
},
"publisher": "Springer Science and Business Media LLC",
"reference": [
{
"key": "1010_CR1",
"unstructured": "www.c19early.org"
},
{
"key": "1010_CR2",
"unstructured": "www.health.gov.au/ministers/the-hon-greg-hunt-mp/media/two-anti-viral-covid-19-treatments-approved"
},
{
"key": "1010_CR3",
"unstructured": "www.ourworldindata.org"
},
{
"author": "A Boretti",
"first-page": "794",
"issue": "5",
"journal-title": "J Taibah Univ Med Sci",
"key": "1010_CR4",
"unstructured": "Boretti A. Pharmacotherapy for COVID-19 infection in the countries of the Cooperation Council for the Arab States. J Taibah Univ Med Sci. 2021;16(5):794.",
"volume": "16",
"year": "2021"
},
{
"author": "A Boretti",
"first-page": "256",
"issue": "3",
"journal-title": "Signa Vitae",
"key": "1010_CR5",
"unstructured": "Boretti A. Analysis of the performances of the covid-19 therapeutic approaches in the United Arab Emirates. Signa Vitae. 2021;17(3):256–63.",
"volume": "17",
"year": "2021"
},
{
"key": "1010_CR6",
"unstructured": "www.health.gov.au/health-alerts/covid-19/treatments/eligibility#eligibility-for-oral-covid19-treatments"
}
],
"reference-count": 6,
"references-count": 6,
"relation": {},
"resource": {
"primary": {
"URL": "https://link.springer.com/10.1007/s10238-023-01010-7"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "On the choice of Molnupiravir and Paxlovid as the only antivirals permitted for COVID-19 infection in Australia",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
"volume": "23"
}
boretti4